Table 2 Clinicopathological characteristics of luminal-papillary MIBC patients from the NAC and TCGA cohorts
Luminal-papillary subset | NAC | p value | TCGA | p value | ||
|---|---|---|---|---|---|---|
LPL-C3 (n = 47) | LPL-Other (n = 77) |  | LPL-C3 (n = 74) | LPL-Other (n = 68) |  | |
Age, median [IQR] | 58 (51–65) | 63 (58–72) | 0.00098 | 61 (54–71) | 70 (64–77) | 0.0034 |
Gender (%) | ||||||
 Female | 12 (26%) | 19 (25%) |  | 16 (22%) | 14 (21%) |  |
 Male | 35 (74%) | 58 (75%) | 1.00 | 58 (78%) | 54 (79%) | 1.00 |
Clinical lymph node stage (%) | ||||||
 cN0 | 36 (77%) | 35 (45%) |  | NA | NA |  |
 cN1–3 | 11 (23%) | 42 (55%) |  | NA | NA |  |
 cNx | 0 (0%) | 0 (0%) | 0.00075 | NA | NA | NA |
Clinical tumor stage (%) | ||||||
 Tis/Ta/T1 |  |  |  |  |  |  |
 cT2 | 23 (49%) | 33 (43%) |  | NA | NA |  |
 cT3 | 18 (38%) | 29 (38%) |  | NA | NA |  |
 cT4 | 6 (13%) | 15 (19%) | 0.64 | NA | NA | NA |
Pathological tumor stage (%) | ||||||
 ypT0/Tis/Ta/T1 | 28 (59%) | 32 (42%) |  | 0 | 0 |  |
 ypT2 | 13 (28%) | 17 (22%) |  | 44 (59%) | 21 (31%) |  |
 ypT3 | 5 (11%) | 20 (26%) |  | 16 (22%) | 28 (41%) |  |
 ypT4 | 1 (2%) | 7 (9%) |  | 7 (9.5%) | 6 (9%) |  |
 ypTx | 0 (0%) | 1 (1%) | 0.047 | 7 (9.5%) | 13 (19%) | 0.0043 |
Pathological lymph node stage (%) | ||||||
 yN0 | 39 (83%) | 35 (45%) |  | 61 (82%) | 36 (53%) |  |
 yN1–3 | 5 (11%) | 24 (31%) |  | 6 (8%) | 17 (25%) |  |
 yNx | 3 (6%) | 18 (23%) | 0.0016 | 7 (9%) | 15 (22%) | 0.0020 |